CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several Fi...
CARsgen Therapeutics is a clinical-stage immune-oncology company committed to the development of First-in-Class and Best-in-Class CAR-T therapeutics.
Founded in 2014, CARsgen is based in Shanghai, with operations in both China and the US. CARsgen has established a broad pipeline of CAR-T product candidates covering several solid and blood tumors in areas of significant unmet medical need. The company has launched several First-in-Class CAR-T clinical trials for the treatment of relapsed/refractory tumors, including CAR-GPC3-T trial for hepatocellular carcinoma (HCC) and squamous lung cancer, CAR-EGFR/EGFRvIII-T trial for glioblastoma.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.